
Join to View Full Profile
4650 W Sunset BlvdLos Angeles, CA 90027
Phone+1 323-669-2121
Fax+1 323-660-7128
Are you Dr. Maurer?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Barry Maurer, MD is a pediatric hematologist/oncologist in Los Angeles, California. He is currently licensed to practice medicine in California.
Education & Training
- University of WashingtonFellowship, Pediatric Hematology/Oncology, 1993 - 1996
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Pediatrics, 1991 - 1993
- Wayne State University School of MedicineInternship, Transitional Year, 1990 - 1991
- Wayne State University School of MedicineClass of 1990
Certifications & Licensure
- CA State Medical License 1992 - 2025
Publications & Presentations
PubMed
- 11 citationsA phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumorsJacob Stephen Thomas, Anthony B. El-Khoueiry, Barry J. Maurer, Susan Groshen, Jacek Pinski
Cancer Chemotherapy and Pharmacology. 2021-01-10 - 4 citationsHydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma.Hwang Eui Cho, Barry J. Maurer, C. Patrick Reynolds, Min H. Kang
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2019-04-01 - 9 citationsCytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.Michael M. Song, Monish Ram Makena, Ashly Hindle, Balakrishna Koneru, Thinh H. Nguyen
Anti-Cancer Drugs. 2019-02-01
Press Mentions
- Kang Receives CPRIT Funding to Support West Texas Pharmacology CoreNovember 9th, 2022
- TTUHSC Researchers Publish Preclinical Data on New Drug Combination to Treat NeuroblastomaNovember 8th, 2019